ImmunoGen Announces Conference Call to Discuss Its 2021 Operating Results

Rhea-AI Summary

ImmunoGen Inc. (NASDAQ: IMGN) has announced a conference call scheduled for February 25, 2022, at 8:00 a.m. ET, to discuss its 2021 operating results and provide a business update. The call can be accessed by phone at (877) 621-5803 using conference ID 5566069 or through the company's website. ImmunoGen is focused on developing next-generation antibody-drug conjugates (ADCs) aimed at improving cancer treatment outcomes and enhancing patient well-being. More details about the company can be found on their website.

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 25, 2022 to discuss its 2021 operating results. Management will also provide a brief update on the business.

CONFERENCE CALL INFORMATION
To access the live call by phone, dial (877) 621-5803; the conference ID is 5566069. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the call, a replay will be available at the same location.

ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220210005022/en/

INVESTOR RELATIONS AND MEDIA

ImmunoGen

Courtney O'Konek

781-895-0600

courtney.okonek@immunogen.com

OR

FTI Consulting

Robert Stanislaro

212-850-5657

robert.stanislaro@fticonsulting.com

Source: ImmunoGen Inc.

FAQ

When is ImmunoGen's conference call regarding their 2021 results?

ImmunoGen's conference call is scheduled for February 25, 2022, at 8:00 a.m. ET.

How can I access the ImmunoGen conference call?

You can access the call by dialing (877) 621-5803 with conference ID 5566069 or via the company's website.

What is the focus of ImmunoGen's business?

ImmunoGen focuses on developing antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.